Ra Capital Management, L.P. Buys 6,146 Shares of Hemab Therapeutics (NASDAQ:COAG) Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. bought 6,146 shares of the stock in a transaction on Monday, June 15th. The shares were acquired at an average cost of $24.89 per share, for a total transaction of $152,973.94. Following the purchase, the insider owned 6,383,114 shares in the company, valued at $158,875,707.46. The trade was a 0.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. bought 61,523 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.98 per share, with a total value of $1,536,844.54.
• On Wednesday, May 20th, Ra Capital Management, L.P. purchased 996 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.94 per share, for a total transaction of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. purchased 3,802 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.97 per share, for a total transaction of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.90 per share, for a total transaction of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.46 per share, with a total value of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. bought 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The stock was bought at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Price Performance

COAG stock opened at $29.24 on Friday. Hemab Therapeutics Holdings, Inc. has a 1 year low of $23.00 and a 1 year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Analyst Upgrades and Downgrades

COAG has been the subject of a number of analyst reports. Wedbush started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price objective for the company. HC Wainwright assumed coverage on shares of Hemab Therapeutics in a research note on Wednesday. They set a “buy” rating and a $40.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price on the stock. Evercore initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price target for the company. Finally, The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Hemab Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.40.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.